NorthWest Biotherapeutics Inc (NWBO)

[edwick709]

It appears that FDA Commissioner Gottlieb's recent , BLUNT statement about cancer and IMMUNOTHERAPY in GENERAL, and specifically about the PRIORITY,in HIS MIND, of "a robust effect" over a "a good "p" value in a messy "crossover" experimental design, has taken off the table the cloud of policy UNCERTAINTY , about the likelihood of DCVAX L securing FDA approval in this "scientific policy atmosphere."
Thank you for the previous research and citation by SEntiment Stocks.

This lifting of the cloud of policy UNCERTAINTY,regarding messy CROSSOVER experimental designs approved by the FDA, appears to be correlated with driving the RECENT escalating and cumulative stock price of NWBO.